mTOR Inhibition for Cancer Therapy: Past, Present and Future

Monica Mita (u. a.)

ISBN 10: 2817804910 / ISBN 13: 9782817804910

Published by Springer, 2015

About this Item

mTOR Inhibition for Cancer Therapy: Past, Present and Future | Monica Mita (u. a.) | Buch | vi | Englisch | 2015 | Springer | EAN 9782817804910 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand.

Seller Inventory # 105437339

Bibliographic Details

• Title: mTOR Inhibition for Cancer Therapy: Past, Present and Future
• Publisher: Springer
• Publication Date: 2015
• Language: English
• ISBN 10: 2817804910
• ISBN 13: 9782817804910
• Binding: Buch
• Condition: Neu
• Dimensions: 241W x 160H x 22D millimeters 241 millimeters width by 160 millimeters height by 22 millimeters depth
• Weight: 685 grams
• Seller catalogs:
  • Bücher

About this title

Synopsis

This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. 

Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.

About the Author

Monica Mita and Alain Mita are Associate Professors of Medicine and Co-Directors of the Experimental Therapeutics Program at the Samuel Oschin Comprehensive Cancer institute, Cedars-Sinai Medical Center in Los Angeles, CA. Eric Rowinsky is Chief Medical Officer, Head of Research and Development, and Executive Vice President at Stemline Therapeutics, Inc. He is also an Adjunct Professor of Medicine at New York University School of Medicine and a cancer drug development consultant at Oncodrugs.